Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.50 |
| ▸ | CCR2 | P41597 | 4/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731549 | 1.00 | PTGES2 (0.50) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL11161302 | 0.83 | PTGES2 (0.50) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL1647074 | 0.81 | PTGES2 (0.66) | PTGES2CCR2SLC40A1ACLYMEN1 | |
| SCHEMBL20714714 | 0.81 | CCR2 (0.59) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL15352788 | 0.80 | CCR4 (0.46) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL15352784 | 0.80 | PTGES2 (0.45) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL29543283 | 0.80 | PTGES2 (0.46) | PTGES2KAT6ATRPV4ALDH1A1TDP1 | |
| SCHEMBL1515862 | 0.80 | PTGES2 (0.46) | PTGES2KAT6ATRPV4ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL28247660 | 0.79 | PTGES2 (0.47) | PTGES2CCR2SLC40A1ACLYKAT6A | |
| SCHEMBL29519135 | 0.77 | TSHR (0.53) | PTGES2SLC40A1CCR4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| CN-122079918-A | Isoxazole biphenyl compounds with CBP BRD and BRD4 BD2 inhibitory activity, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| CN-120554257-A | Synthetic method of high-purity 3-chloro-2-fluorobenzenesulfonamide | 常州大学 | 2025-08-29 | — | — | CN | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118290379-A | Preparation method of novel agricultural multifunctional substance and application of novel agricultural multifunctional substance in aspects of resisting virus, inhibiting bacteria and promoting plant growth | 贵州工业职业技术学院 | 2024-07-05 | — | — | CN | disclosed |
| CN-117430574-B | Benzofuran derivative and preparation method and application thereof | 潍坊医学院 | 2024-03-22 | — | — | CN | disclosed |
| CN-117720498-A | Synthesis of novel coumarin derivative containing sulfonamide fragments and preparation method and application of composition of novel coumarin derivative | 贵州工业职业技术学院 | 2024-03-19 | — | — | CN | disclosed |
| CN-117430574-A | Benzofuran derivative and preparation method and application thereof | 潍坊医学院 | 2024-01-23 | — | — | CN | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1610753-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004073634-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | PTGES2 761/4885CCR2 2315/4885SLC40A1 4037/4885 |
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | PTGES2 2076/4885CCR2 689/4885SLC40A1 2458/4885 |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | PTGES2 153/4885CCR2 3/4885SLC40A1 2467/4885 |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | PTGES2 516/4885CCR2 4/4885SLC40A1 3214/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | PTGES2 516/4885CCR2 4/4885SLC40A1 3214/4885 |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | PTGES2 1207/4885CCR2 3797/4885SLC40A1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.